NCT05323617View on ClinicalTrials.gov

Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

August 31, 2023

Primary Completion Date

February 25, 2025

Study Completion Date

February 25, 2025

Conditions

Severe Aplastic Anemia (SAA)

Interventions

DRUG

Romiplostim

Administered as a subcutaneous injection.

DRUG

Antithymocyte Globulin

Horse or rabbit antithymocyte globulin administered as an intravenous infusion.

DRUG

Cyclosporine A

Administered orally.

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY

NCT05323617 - Efficacy of Romiplostim in Treatment of SAA in Adults Previously Untreated With or Refractory to Immunosuppressive Therapy | Biotech Hunter | Biotech Hunter